UPDATE: Jefferies Raises PT on Celgene Following Multiple Myeloma Survey

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Thursday, Jefferies analyst Thomas Wei reiterated a Buy rating on Celgene Corporation (NASDAQ: CELG), and raised the price target from $114.00 to $140.00.In the report, Wei noted, “We conducted a Medpanel survey of 59 U.S. physicians to determine opinions on current and future treatment options for multiple myeloma. Specifically, we found more favorable feedback on Pomalyst, as well as the potential for significant expansion of Revlimid frontline use. Based on our survey, we are raising our PT from $114 to $140.”Celgene Corporation closed on Wednesday at $120.81.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!